Phylo

Founded in 2025, Phylo, Inc. offers a collaborative bioinformatics platform aimed at improving scientific data workflows. The company was established by Kexin Huang and Yuanhao Qu and has not undergone any notable pivots or changes since its inception. Its headquarters is situated in South San Francisco, US. Recently, Phylo, Inc.Phylo's primary offering, Biomni Lab, serves as a collaborative bioinformatics platform designed to enhance the efficiency and accuracy of biological research. This advanced tool integrates seamlessly within the biomedical research ecosystem, allowing biologists to engage with AI-driven agents for diverse tasks such as protein design, multi-omics data analysis, and the synthesis of literature insights. By automating complex processes that traditionally consume weeks of labor, Biomni Lab accelerates discovery and fosters innovative hypotheses through its critical analysis capabilities.Phylo generates revenue primarily through subscription-based access to its Biomni Lab services, catering to both individual researchers and institutional clients. Clients typically engage with the service on a recurring basis, utilizing tiered subscription plans that provide varying levels of access and features according to their specific research needs. For instance, institutions may opt for an enterprise-level subscription that encompasses multiple user licenses and enhanced computational resources, while individual researchers might select a personal plan for streamlined access.In February 2026, Phylo, Inc. Future product developments are expected to enhance the features of Biomni Lab, although specific release dates have not been disclosed. Additionally, Phylo aims to expand its services into new markets, particularly targeting increased engagement in Europe and North America by 2027.

1. Seed

   Feb 3, 2026

   Amount

   $14M

   Investors

   Locked